SRPT (Sarepta Therapeutics,, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SRPT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Ryan Ho-Yan Wong | Chief Financial Officer | F | — | — |
| 2026-09-08 | Ian Michael Estepan | Chief Operating Officer | F | — | — |
| 2026-09-08 | Cristin Rothfuss | EVP, General Counsel | F | — | — |
| 2026-09-08 | Louise Rodino-Klapac | President, R&D and Tech Ops | F | — | — |
| 2026-07-29 | MICHAEL SEVERINO | Chief Executive Officer | A | — | — |
| 2026-06-05 | Richard Barry | Director | A | — | — |
| 2026-06-05 | Michael Andrew Chambers | Director | A | — | — |
| 2026-06-05 | Claude Nicaise | Director | A | — | — |
| 2026-06-05 | Deirdre P Connelly | Director | A | — | — |
| 2026-06-05 | M KATHLEEN BEHRENS | Director | A | — | — |
| 2026-06-05 | Hans Lennart Rudolf Wigzell | Director | A | — | — |
| 2026-06-05 | Stephen Mayo | Director | A | — | — |
| 2026-06-05 | Kathryn Jean Boor | Director | A | — | — |
| 2026-03-13 | Cristin Rothfuss | EVP, General Counsel | F | — | — |
| 2026-03-13 | Stephen Mayo | Director | Sell | — | — |
| 2026-03-13 | Louise Rodino-Klapac | President, R&D and Tech Ops | F | — | — |
| 2026-03-13 | Ryan Ho-Yan Wong | Chief Financial Officer | F | — | — |
| 2026-03-13 | Ian Michael Estepan | Chief Operating Officer | F | — | — |
| 2026-03-11 | Ian Michael Estepan | Chief Operating Officer | F | — | — |
| 2026-03-11 | Louise Rodino-Klapac | President, R&D and Tech Ops | F | — | — |
| 2026-03-11 | Cristin Rothfuss | EVP, General Counsel | F | — | — |
| 2026-03-11 | Ryan Ho-Yan Wong | Chief Financial Officer | F | — | — |
| 2026-03-03 | Louise Rodino-Klapac | President, R&D and Tech Ops | MIXED | — | — |
| 2026-03-03 | Ian Michael Estepan | Chief Operating Officer | MIXED | — | — |
| 2026-03-03 | Ryan Ho-Yan Wong | Chief Financial Officer | F | — | — |
| 2026-03-03 | Cristin Rothfuss | EVP, General Counsel | F | — | — |
| 2026-03-02 | Ian Michael Estepan | Chief Operating Officer | M | — | — |
| 2026-02-27 | Louise Rodino-Klapac | President, R&D and Tech Ops | A | — | — |
| 2026-02-27 | Ian Michael Estepan | Chief Operating Officer | A | — | — |
| 2026-01-29 | M KATHLEEN BEHRENS | Director | MIXED | — | — |
| 2026-01-29 | Claude Nicaise | Director | MIXED | — | — |
| 2025-12-19 | Michael Andrew Chambers | Director | MIXED | — | — |
| 2025-12-18 | Ian Michael Estepan | Chief Operating Officer | Sell | — | — |
| 2025-12-10 | Ryan Ho-Yan Wong | Chief Financial Officer | F | — | — |
| 2025-12-09 | DOUGLAS S INGRAM | Chief Executive Officer | A | — | — |
| 2025-12-02 | Cristin Rothfuss | EVP, General Counsel | F | — | — |
| 2025-11-19 | Louise Rodino-Klapac | President, R&D and Tech Ops | F | — | — |
| 2025-09-05 | Cristin Rothfuss | EVP, General Counsel | A | — | — |
| 2025-09-05 | Ian Michael Estepan | Chief Operating Officer | A | — | — |
| 2025-09-05 | Ryan Ho-Yan Wong | Chief Financial Officer | A | — | — |
| 2025-09-05 | Louise Rodino-Klapac | President, R&D and Tech Ops | A | — | — |
| 2025-08-06 | Louise Rodino-Klapac | President, R&D and Tech Ops | A | — | — |
| 2025-08-06 | Ian Michael Estepan | Chief Operating Officer | A | — | — |
| 2025-08-06 | Bilal Arif | Chief Tech Ops Officer | A | — | — |
| 2025-08-04 | Ryan Ho-Yan Wong | Chief Financial Officer | F | — | — |
| 2025-05-19 | Richard Barry | Director | M | — | — |
| 2025-05-15 | Richard Barry | Director | M | — | — |
| 2025-03-13 | Claude Nicaise | Director | MIXED | — | — |
| 2025-03-11 | M KATHLEEN BEHRENS | Director | A | — | — |
| 2025-03-11 | Claude Nicaise | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,993,542 | — |
| — | Chief Executive Officer | 756,104 | — |
| — | Director | 504,027 | — |
| — | Chief Executive Officer | 440,307 | — |
| — | Director | 224,357 | — |
| — | President, R&D and Tech Ops | 203,900 | — |
| — | Chief Operating Officer | 177,184 | — |
| — | EVP, General Counsel | 130,984 | — |
| — | Chief Financial Officer | 121,792 | — |
| — | EVP, General Counsel | 115,519 | — |
| — | President & CEO | 71,229 | — |
| — | Director | 67,194 | — |
| — | EVP, General Counsel | 48,442 | — |
| — | Director | 48,407 | — |
| — | Director | 42,830 | — |
| — | Director | 42,098 | — |
| — | Chief Customer Officer | 33,659 | — |
| — | Chief Tech Ops Officer | 32,500 | — |
| — | SVP, Chief Regulatory Affairs | 31,936 | — |
| — | EVP, CFO & CBO | 30,851 | — |
| — | President and CEO | 29,552 | — |
| — | Director | 25,138 | — |
| — | Director | 22,100 | — |
| — | Director | 18,640 | — |
| — | EVP | 14,099 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SRPT quote page; the site-wide leaderboard is on the insider transactions hub.